# Remission in Subjects With Crohn's Disease, 1 Year Phase

> **NCT00055497** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 276 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Double-blind (DB) adalimumab placebo
- **BIOLOGICAL:** DB adalimumab 40 mg eow
- **BIOLOGICAL:** DB adalimumab 40 mg ew
- **BIOLOGICAL:** OL adalimumab 40 mg

## Key facts

- **NCT ID:** NCT00055497
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2005-01
- **Final completion:** 2008-12
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2011-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00055497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00055497, "Remission in Subjects With Crohn's Disease, 1 Year Phase". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00055497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*